Cynata Therapeutics Limited (CYYNF) Stock Price & Analysis
Cynata Therapeutics Limited (CYYNF) — price $0.0072 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.42M.
Educational signal · not a buy or sell recommendation · How to read this
Cynata Therapeutics Limited · CYYNF
Cynata Therapeutics Limited specializes in developing and commercializing proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications in Australia.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0072 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0014 – $0.2225 | |
| Market capitalisation | $2.42M | — |
| Shares traded on the day | 220 |
Price & events
Other perspectives
Council score for Cynata Therapeutics (CYYNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cynata Therapeutics (CYYNF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cynata Therapeutics Limited (CYYNF) is the company analyzed here. It employs 2 people and is led by Kilian Kelly. In Q2 FY2025 it reported revenue of A$2M and net income of -A$4M. The market values it at $2.42M.
What do the latest results show for Cynata Therapeutics (CYYNF)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of A$2M.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | A$2M | -A$4M | -A$0.02 (diluted) |
What are the financial strengths and risks for Cynata Therapeutics (CYYNF)?
Short answer · as of
The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.64.
What should you watch next at Cynata Therapeutics (CYYNF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.70M · EPS -0.02 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q2 FY2025) was filed Dec 31, 2024 — 17 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.70M
- EPS estimate
- $-0.02
Measured against a quoted price of $0.0072 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CYYNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CYYNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Cynata Therapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the CYYNF research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What are the implications of CYYNF trading on the OTC market, specifically the 'OTC Other' tier?
Trading on the OTC market, particularly the 'OTC Other' tier, carries several implications for CYYNF and its investors. This can lead to limited transparency, making it challenging for investors to access comprehensive and timely financial or operational information.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 7 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com